{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:54:00Z","timestamp":1775638440634,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.leukres.2007.10.019","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T16:36:44Z","timestamp":1196959004000},"page":"930-935","source":"Crossref","is-referenced-by-count":15,"title":["Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia"],"prefix":"10.1016","volume":"32","author":[{"given":"Wei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Xuan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Jiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Lan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Lan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2007.10.019_bib1","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.10.019_bib2","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial","volume":"22","author":"Thomas","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.10.019_bib3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2007.10.019_bib4","first-page":"S127","article-title":"The U.S. trials in adult acute lymphoblastic leukaemia","volume":"83","author":"Larson","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2007.10.019_bib5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM199808273390907","article-title":"Acute lymphoblastic leukemia","volume":"339","author":"Pui","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2007.10.019_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2007.10.019_bib7","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.1986.4.12.1732","article-title":"Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine","volume":"4","author":"Murphy","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.10.019_bib8","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/sj.leu.2400861","article-title":"The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia","volume":"11","author":"Koller","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2007.10.019_bib9","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.10.019_bib10","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.10.019_bib11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.10.019_bib12","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/cncr.10365","article-title":"Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma\/leukemia","volume":"94","author":"Cortes","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2007.10.019_bib13","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.10.019_bib14","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2007.10.019_bib15","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.10.019_bib16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/10428190600632832","article-title":"Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy","volume":"47","author":"Lane","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2007.10.019_bib17","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood-2003-10-3560","article-title":"Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial","volume":"104","author":"Hunault","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.10.019_bib18","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212607004018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212607004018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T06:08:20Z","timestamp":1588140500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212607004018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0145212607004018"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2007.10.019","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}